Adverse Effects

Latest News

Roxadustat Demonstrates Noninferiority in Chemotherapy-Induced Anemia

May 23rd 2023

Plans have been made to file a new drug application in China for roxadustat as a treatment for chemotherapy-induced anemia in those with non-myeloid malignancies.

Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.

Tocilizumab May Reduce CRS Recurrence in Teclistamab-Treated Multiple Myeloma

By Russ Conroy

May 12th 2023

A senior physician’s assistant from Johns Hopkins examines why adverse effect management is so crucial and reviews how to help maintain quality of life while undergoing treatment.

Importance of AE Management With TKI/Immunotherapy Treatments

By Ariana Pelosci

April 15th 2023

EU's CHMP Recommends Injection Against Pediatric Chemo-Induced Ototoxicity

By Russ Conroy

April 9th 2023

In addition to granting fast track designation to RRx-001, the FDA accepts an investigational new drug application for the agent to reduce and/or prevent radiation- and chemotherapy-associated oral mucositis.

NLRP3 Inhibitor/Nrf2 Upregulator Receives FDA FTD for Severe Oral Mucositis

By Hayley Virgil

April 3rd 2023

Latest CME Events & Activities

Tumor Board: How The Experts Approach Personalized Care Plans in ER-Positive Breast Cancer

Community Practice Connections™: Translating Recent Evidence on CAR T-Cell Therapy to the Real-World Management of Lymphoid Malignancies

7th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards

Community Practice Connections™: Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes

Evolving Paradigms in Transplant-Related CMV Prevention and Management: Setting Foundations for Improved Patient Outcomes

CAR T-Cell Therapy in Multiple Myeloma: Key Considerations for Patient Selection, Transplant, and Applying Recent Data

Optimizing ASCT in Patients With Multiple Myeloma and Non-Hodgkin Lymphoma Through Stem Cell Mobilization Techniques

Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future

Medical Crossfire®: Experts Address Burning Questions in DLBCL—Sequencing CD19-Targeted Therapies, Strategies Post-CAR T Relapse, Novel Agents, and More!

Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care

B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence

Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

Medical Crossfire®: Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

Live “Hot Seat”: Experts Face Your Hot-Button Questions on Maximizing PARP Inhibitors in Patients with CRPC

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies

Medical Crossfire®: Everything You Need to Know About the PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

On-Demand Video Updates from the Annual Oncology Meeting

Medical Crossfire®: Leveraging Multidisciplinary Teams in Early Stage Breast Cancer When the Goal is Cure

<1 2

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777